Le Lézard
Classified in: Health, Business
Subjects: CON, CXP

ivWatch Extends Its Global Reach Signing Three New Distribution Partners


Company Strengthens International Expansion and Broadens the Availability of Continuous IV Monitoring Solutions to Strategic Markets

NEWPORT NEWS, Va., Aug. 11, 2022 /PRNewswire/ -- Today, ivWatch, LLC, an innovative IV safety company working to eliminate harm caused by infiltration and extravasation events, announced three new strategic distribution partnerships internationally. Bameco in Austria, Warba Medical Supplies in Kuwait, and Mustafa Sultan Science & Industry Co, LLC in Oman have each signed exclusive agreements to promote, sell, and support ivWatch's continuous monitoring products in their markets. ivWatch's novel technologies will complement and bolster their existing portfolios of intravenous products provided to hospitals and other health care facilities.

ivWatch solutions continue to be available in more countries throughout the globe and with the addition of Austria, Kuwait, and Oman, clinicians will now be able to improve their bedside decision-making with real-time IV infiltration data. Continuous IV site monitoring provides accurate and precise insights to detect infiltrations and extravasations at their earliest stages. ivWatch's proprietary algorithm detects infiltrations promptly and notifies clinicians of adverse IV therapy events often hours before they are detectable by visual or tactile examination.1

"At ivWatch, we are on a steadfast mission to improve IV safety globally and we are extremely passionate about partnering with likeminded innovators who share that same relentless pursuit to advance patient safety," said Chuck Egress, Vice President of Business Development and Emerging Markets at ivWatch. "IV infiltrations and extravasations are a major global patient safety concern, and these new partnerships provide increased access to advanced safety solutions to help end complications and improve patient outcomes in IV therapy."

ivWatch has over 60 patents worldwide and received its first FDA clearance in 2015 for its IV site monitoring system that consists of an ivWatch Patient Monitor and a reusable optical biosensor that uses visible and near-infrared light to continuously measure changes in the optical properties of the tissue near an IV insertion site. In 2020, the company expanded its portfolio of sensor solutions and received FDA clearance for a single-use, miniaturized biosensor that is cleared for all patient age groups, sizes, and skin tones. Both sensors work seamlessly with the intuitive user interface on the Patient Monitor, which issues audible and visual "Check IV" alerts for the clinician to assess the IV site. ivWatch technology performs with high accuracy, intelligence, and low false alarm rates, which is critical to improving patient outcomes.

To learn more about ivWatch, visit www.ivWatch.com or follow the Company's social media platforms for the latest updates on new continuous monitoring innovations in IV safety. 

1 Doellman, D. and Rineair, S. (2019) The use of optical detection for continuous monitoring of pediatric IV sites. Journal of the Association for Vascular Access: Summer 2019, Vol. 24, No. 2, pp. 44-47.

About ivWatch, LLC
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. Our innovative continuous monitoring IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, LinkedIn @ivWatch or visit www.ivWatch.com.

SOURCE ivWatch, LLC


These press releases may also interest you

at 19:30
Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology...

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 17:58
More than 200 workers at American Medical Response (AMR) in Springfield and Greenfield have voted overwhelmingly to join Teamsters Local 404....

at 17:54
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their...



News published on and distributed by: